RedHill Biopharma Divests Talicia Business to Apotex for USD 18 Million Upfront
RedHill Biopharma has divested its 70 percent interest in Talicia to Apotex in a deal valued at up to USD 53 million, including potential sales milestones.
Apotex Health Corp | 01/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy